Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
Date:3/8/2012

the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication, regulatory review and potential approval of Arena's most advanced drug candidate, lorcaserin; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review is uncertain and Arena's applications for regulatory approval of lorcaserin may not be reviewed when anticipated; the EU application is subject to acceptance and confirmation by the EU regulatory agency that it is sufficiently complete to permit a substantive review; the FDA may not complete its review of the lorcaserin application by the PDUFA date; the occurrence, timing and results of FDA advisory committee meetings relating to lorcaserin and other drug candidates; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review or approval; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the tim
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
2. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
3. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
4. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
5. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
6. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
8. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
9. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
10. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
11. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
(Date:1/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System ... accompanying instrumentation to place and insert the screw accurately ... tissue (e.g. ligament) repair or reconstruction as it holds ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... May 5, 2011 Cardiac Network, Inc. (Other OTC: CNWI.PK) ... 1-for-750 reverse stock split (the "Reverse Stock Split"). The Reverse ... and trading on May 6, 2011 (the "Effective Date"). On ... from "CNWI" to "CNWID" for approximately 20 business days, after ...
... ARAY ), a global leader in the field ... of fiscal year 2011, ended March 31, 2011. ... total revenue of $54.7 million, an increase of five percent ... of fiscal 2010. Total revenue during the third quarter of ...
Cached Medicine Technology:Cardiac Network Announces Reverse Stock Split 2Accuray Announces Results for Third Quarter of Fiscal 2011 2Accuray Announces Results for Third Quarter of Fiscal 2011 3Accuray Announces Results for Third Quarter of Fiscal 2011 4Accuray Announces Results for Third Quarter of Fiscal 2011 5Accuray Announces Results for Third Quarter of Fiscal 2011 6
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... - Men are four times more likely to develop liver ... hormones androgen and estrogen. Although this gender difference has been ... estrogens prevent -- and androgens promote -- liver cancer remain ... week from the lab of Klaus Kaestner, PhD, professor of ...
... People taking blood thinners who suffer a minor head injury ... study included 87 patients taking warfarin (brand name Coumadin) who ... department. Warfarin is widely prescribed to prevent blood clots. ... CT scan, hemorrhage lesions were seen in five of the ...
... Reporter , WEDNESDAY, Jan. 18 (HealthDay News) -- New research suggests ... density scan -- a test that helps measure the strength of ... 15 years before getting another scan. However, women who show ... than that, the study authors noted. "Women who had good ...
... Why does health care need to be redesigned? First the ... yields little value for patients and society. Second it,s fixable. ... Happen are convinced of it. The contributors to the book ... transform care for their own patients within their own practices and ...
... problems in one of the body,s most complex organs ... by Wayne State University researchers. Howard Matthew ... science, recently received a $550,000 grant from the National ... liver metabolism that can be used to analyze and ...
... In a study investigating immune response in cancer, ... the University of South Florida have found that interaction ... myeloid-derived suppressor cells (MDSC) cells that play a ... the nature of MDSC-mediated suppression. By contrast, the same ...
Cached Medicine News:Health News:Gender differences in liver cancer risk explained by small changes in genome 2Health News:Some Women Can Go Longer Between Bone Checks: Study 2Health News:Some Women Can Go Longer Between Bone Checks: Study 3Health News:Sooner or later, we are all patients 2Health News:NSF grant will aid Wayne State professors' mathematical modeling of fatty liver predictors 2Health News:Study finds potential key to immune suppression in cancer 2
... packaged in easy open, single-use foil-laminated ... saturated with precisely the correct amount ... sterilized, ensuring the safest possible product ... is an antiseptic, microbicidal skin cleanser ...
... Aplicare's Saturated Swabsticks ... open, single-use foil-laminated pouches. ... is saturated with precisely ... solution. Each package is ...
... Swabsticks are packaged in easy open, ... Swabstick is saturated with precisely the ... is terminally sterilized, ensuring the safest ... acts as a prophylactic anti-infective agent ...
... Aplicare's Saturated Swabsticks are packaged ... 4 inch Swabstick is saturated ... of solution. Each package is ... possible product for the patient. ...
Medicine Products: